Acoziborole resistance associated mutations in Trypanosoma brucei CPSF3
PLOS Pathogens · 03.03.2026 · 22 (3) · e1013764
DOI: 10.1371/journal.ppat.1013764 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, online erschienen am 03.03.2026. Verfasst von Melanie Ridgway und 6 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Life Sciences, University of Dundee, Dundee, United Kingdom. Hauptthemen laut MEDLINE: Trypanosoma brucei brucei, Drug Resistance, Trypanocidal Agents, Cleavage And Polyadenylation Specificity Factor. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust.
Abstract (Originalsprache)
Acoziborole is a safe, single dose, oral therapy, for treatment of both early and late-stage sleeping sickness, a deadly disease caused by African trypanosomes. Other benzoxaboroles show efficacy against other trypanosomatids, apicomplexans, fungi, bacteria, and viruses. Acoziborole targets the trypanosome pre-mRNA processing endonuclease, cleavage and polyadenylation specificity factor 3 (CPSF3), and triggers CPSF3 degradation, but it remains unclear whether additional mechanisms contribute to efficacy. We used oligo targeting for site saturation mutagenesis of the native CPSF3 gene. Among >1,500 edits around the putative drug binding site, only Asn 232 His edits conferred moderate resistance to acoziborole. Using a combinatorial oligo targeting method we edited multiple sites simultaneously, including sites that differ in human CPSF3, and found that an Asn 232 His, Tyr 383 Phe, Asn 448 Gln triple-mutant strain was > 40-fold resistant to acoziborole. We used gene tagging to show that all three edits were on the same allele, and to show that triple-mutant CPSF3 was highly resistant to rapid acoziborole and proteasome-dependent degradation. Computational modelling revealed how the combinatorial mutations can disrupt acoziborole – CPSF3 interactions by introducing steric clash and by disrupting hydrophobic and water-mediated interactions. We conclude that acoziborole safety and efficacy can be explained by selective affinity for, and rapid turnover of, trypanosome CPSF3.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Faculty of Life Sciences, University of Dundee, Dundee, United Kingdom.
- Drug Discovery Unit, Faculty of Life Sciences, University of Dundee, Dundee, United Kingdom.
ORCID-Profile: David Horn
Förderung
- Wellcome Trust
Zitieren
APA
Ridgway, M., Novotná, M., Mendoza-Martinez, C., Tinti, M., Altmann, S., Sloan, G., & Horn, D. (2026). Acoziborole resistance associated mutations in Trypanosoma brucei CPSF3. PLOS Pathogens, 22(3), e1013764. https://doi.org/10.1371/journal.ppat.1013764
Vancouver
Ridgway M, Novotná M, Mendoza-Martinez C, Tinti M, Altmann S, Sloan G, et al. Acoziborole resistance associated mutations in Trypanosoma brucei CPSF3. PLOS Pathogens. 2026;22(3):e1013764. doi:10.1371/journal.ppat.1013764
BibTeX
@article{Ridgway2026,
author = {Ridgway, Melanie and Novotná, Markéta and Mendoza-Martinez, Cesar and Tinti, Michele and Altmann, Simone and Sloan, Graeme and Horn, David},
title = {Acoziborole resistance associated mutations in Trypanosoma brucei CPSF3},
journal = {PLOS Pathogens},
year = {2026},
volume = {22},
number = {3},
pages = {e1013764},
doi = {10.1371/journal.ppat.1013764}
}
EUVIMED